Apatinib for Resectable Colorectal Cancer (NCT03228043) | Clinical Trial Compass
WithdrawnNot Applicable
Apatinib for Resectable Colorectal Cancer
Stopped: It's not possible to complete in our hospital.
China0Started 2020-03-01
Plain-language summary
Objective: To compare the outcome of patients with colorectal cancer who treated with adjuvant therapy or Apatinib with adjuvant therapy postoperatively.
Language: English.
Who can participate
Age range
18 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. ECOG performance status score: 0-1.
. All colorectal cancer patients underwent curative intent surgery
. Patients in stage Ⅱ(Any T, N0, M0) with multiple high-risk factors or stage Ⅲ (any T, N1-2, M0) which confirmed by pathology.
. Patients who did not receive other treatments for colorectal adenocarcinoma after surgery;
. The main organ function is good, patients must meet the following requirements with 14 days before using Apatinib:
. The surgical incision has been healed, and no bleeding tendency;
. Sign informed consent;
. Compliance is good, family members agreed to accept survival follow-up.
Exclusion criteria
. Patients with other malignancies, except for cured skin basal cell carcinoma and cervical cancer in situ.
. Participated in other drug clinical trials within four weeks.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
. Have a variety of factors that affect oral medication (such as unable to swallow, chronic diarrhea and intestinal obstruction, etc.).
. Have a history of bleeding, screening within 4 weeks before any serious grade to CTCAE4.0 3 degrees or more bleeding events.
. Patients with central nervous system metastases or a history of central nervous system metastases before screening. For patients with suspected central nervous system metastases, CT or MRI examinations must be performed within 28 days prior to randomization to exclude central nervous system metastasis.
. History of high blood pressure can not be controlled with a single antihypertensive drug therapy (With a systolic blood pressure\> 140 mmHg, diastolic blood pressure\> 90 mmHg. A history of unstable angina within 3 months or a new diagnosis of angina within 6 months (Including QTcF: male ≥ 450 ms, female ≥470 ms) required long-term use of antiarrhythmic drugs and New York Heart Association classification ≥ Class II cardiac insufficiency.
. Urinary protein ≥ ++ and urine protein\> 1.0 g in 24 hours.
. Patients with anastomotic fistula, pancreatic fistula or anastomotic stenosis and other serious postoperative complications.